Anhedonia, Development, and Emotions: Phenotyping and Therapeutics (ADEPT)
Depression, Anhedonia
About this trial
This is an interventional treatment trial for Depression focused on measuring depression, anhedonia
Eligibility Criteria
Inclusion Criteria:
Phase 1 (all participants)
- Current DSM-5 depressive disorder
- Severity ≥ 12 on MADRS
- Moderate-severe anhedonia (75% of sample) or low anhedonia (25% of sample)
Phase 2 (for participants in TBS and ketamine phase, in addition to above)
• ≥ 1 failed antidepressant trial (for qualification for Phase 2 of study and definition of non-response to TMS in order to be eligible for ketamine) = Treatment for at least 6 weeks with an antidepressant medication reaching recommended dosage for adults for at least 3 weeks of the treatment (e.g., 20 mg fluoxetine)
Exclusion Criteria:
Phase 1 (all participants)
- Lifetime psychosis, bipolar disorder, autism spectrum disorder, or developmental disorder
- Serious, unstable neurological disorder (e.g., seizure disorder)
- Brain injury with loss of consciousness
- Daily nicotine use
- Moderate-severe substance use disorder, past 6 mos.
- MRI contraindications (e.g., metal in body)
Phase 2 (for participants in TBS and ketamine phase, in addition to above)
- Serious, unstable respiratory or cardiovascular illness
- Pre-TBS: Alcohol binge in past week or > 3 drinks/day in past 3 days
- Pre-ketamine: use of MAOIs in past 2 weeks
- Medication: SNRIs, bupropion, antipsychotics, or stimulants
- Pregnancy
- High blood pressure
- Current illicit stimulant use
- Lifetime recreational ketamine or PCP use
Sites / Locations
- Loeffler BuildingRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
TMS and PAT
TMS and PAT, then Ketamine
All open label with no randomization to placebo
All open label with no randomization to placebo